文献速递痛风与晶体性关节病

NOR-Gout研究12个月结果:达标治疗与紧密控制策略下血尿酸目标的达成及预测因素

12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target.
PubMed 文献 · RMD Open · 2021-01-01

NOR-Gout研究是一项单中心真实世界观察性研究,纳入211例近期痛风发作且血尿酸>360 µmol/L的患者,采用护师主导信息联合降尿酸治疗的达标治疗与紧密控制策略。12个月时平均血尿酸从500降至311 µmol/L,85.5%患者达到<360 µmol/L目标;至少每周饮酒和认为药物被过度使用的信念降低达标几率,而关节炎症状自我效能较高增加达标可能性。

要点

  • 达标治疗联合紧密控制可使85.5%痛风患者在12个月达到血尿酸<360 µmol/L。
  • 至少每周饮酒和认为药物被过度使用的信念与达标几率降低相关。
  • 关节炎症状自我效能较高与达标可能性增加相关。

核心结论

  • 采用达标治疗联合紧密控制策略,多数痛风患者可达到目标血尿酸水平。
  • 较少自报饮酒、较低药物过度使用信念和较高自我效能与治疗成功相关。

研究设计与样本

  • 单中心真实世界观察性研究,连续纳入近期痛风发作且血尿酸>360 µmol/L的患者211例,平均年龄56.4岁,病程7.8年,95%为男性,186例完成12个月研究。
  • 采用护师主导的痛风信息联合降尿酸治疗的达标治疗策略,在基线、1、2、3、6、9和12个月进行紧密控制评估。
  • 治疗目标为血尿酸<360 µmol/L,采用多变量逻辑回归分析达标预测因素,报告OR及95%CI。

主要发现

  • 平均血尿酸从基线500 µmol/L降至12个月时311 µmol/L,85.5%患者达到治疗目标。
  • 至少每周饮酒 versus 更少频率饮酒的OR为0.14(95%CI 0.04至0.55),降低达标几率。
  • 认为药物被过度使用的信念每增加1单位的OR为0.77(95%CI 0.62至0.94),降低达标几率。
  • 关节炎症状自我效能每增加10单位的OR为1.49(95%CI 1.09至2.05),增加达标可能性。

关键数值与推荐

  • 治疗目标为血尿酸<360 µmol/L。
  • 纳入标准为近期痛风发作且血尿酸>360 µmol/L(>6 mg/dL)。
  • 至少每周饮酒 versus 更少频率饮酒的OR为0.14(95%CI 0.04至0.55)。
  • 认为药物被过度使用的信念每增加1单位的OR为0.77(95%CI 0.62至0.94)。
  • 关节炎症状自我效能每增加10单位的OR为1.49(95%CI 1.09至2.05)。

临床怎么用

  • 对痛风患者可采用护师主导信息联合降尿酸治疗的达标治疗与紧密控制策略以促进血尿酸达标。
  • 评估患者饮酒频率、对药物过度使用的信念及关节炎症状自我效能,有助于识别达标困难的高风险患者。

局限性

  • 单中心研究,95%为男性,结果外推需谨慎。
  • 为观察性研究,所报告的关联不能确定因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Gout is often not adequately treated, and we aimed to apply urate lowering treatment (ULT) combined with individual information to achieve target serum urate (sUA) in clinical practice, and to identify predictors of achievement of this sUA target. METHODS: Patients with a recent gout flare and sUA >360 µmol/L (>6 mg/dL) were consecutively included in a single-centre study and managed with a treat-to-target approach combining nurse-led information about gout with ULT. All patients were assessed with tight controls at baseline, 1, 2, 3, 6, 9 and 12 months including clinical examination, information on demographics, lifestyle, self-efficacy and beliefs about medicines. The treatment target was sUA <360 µmol/L and multivariable logistic regression was used to identify predictors of target attainment with ORs and 95% CIs. RESULTS: Of 211 patients (mean age 56.4 years, disease duration 7.8 years, 95% males), 186 completed the 12-month study. Mean sUA levels decreased from baseline mean 500 to 311 µmol/L at 12 months with 85.5% achieving the treatment target. Alcohol consumption at least weekly versus less frequently (OR 0.14; 95% CI 0.04 to 0.55) as well as beliefs in overuse of medicines (OR per unit 0.77; 95 CI 0.62 to 0.94) decreased the chance of reaching the treatment target, while higher self-efficacy for arthritis symptoms (OR 1.49 per 10 units; 95% CI 1.09 to 2.05) increased the likelihood. CONCLUSIONS: This study shows that target sUA can be achieved with ULT in most patients. Less self-reported alcohol consumption, low beliefs in overuse of medicines and higher self-efficacy are associated with treatment success.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Uhlig T, Karoliussen LF, Sexton J, et al. 12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target. RMD Open. 2021. PMID: 33782189. doi:10.1136/rmdopen-2021-001628

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。